The immuno-oncology trial evaluates the efficacy and safety of the study drugs when given in combination for patients with this type of cancer. Another purpose of the study is to see which tumor markers lead to better results in participants treated with the study drugs. Nivolumab and ipilimumab work in slightly different ways to activate the immune system and help the body’s immune system to work against tumor cells. The combination of these drugs is already approved by the FDA to treat advanced melanoma.